What’s next for Bristol Myers' relatlimab?

If in relatlimab Bristol Myers Squibb was looking for a less toxic drug than Yervoy to complement Opdivo then the first pillar of this strategy is in place. The Opdivo/relatlimab combo, now trademarked Opdualag, was last week approved for front-line melanoma, with no delay and no nasty label surprises.